AI study led by In­sil­i­co's Alex Zha­voronkov bol­sters case for faster, cheap­er drug dis­cov­ery

Drug de­vel­op­ment is an ar­du­ous and ex­pen­sive busi­ness. The promise of ar­ti­fi­cial in­tel­li­gence is that ma­chines can wean man­u­fac­tur­ers away from the breadth of re­sources it takes to dis­cov­er a po­ten­tial­ly po­tent com­pound, and lever­age the med­ical con­di­tions it could be used to treat. Alex Zha­voronkov, whose Hong Kong-based AI-shop In­sil­i­co Med­i­cine has en­trenched it­self in the ten­ta­cles of bio­phar­ma R&D, now has some da­ta to bol­ster the fer­vor and in­vest­ment that AI has drummed up.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER